Table 1. Summary of the studies: prognosis according to CD44+/CD24- BCSC marker expression.

Author	Year	Study population	Findings
Chekhun et al. [29]	2015	132 patients with BC stage 1-2	Statistical significance was found between the presence of CD44+/CD24- in metastatic regional lymph nodes along with overall survival (OS) in cases with basal-like and molecular subcategories
Li et al. [30]	2010	Immunohistochemistry of 103 cases of invasive micropapillary carcinoma (IMPC) and 94 cases of invasive ductal carcinoma (IDC)	CD44+/CD24- marker was observed in tumor cells in micropapillary and also in its stroma. Moreover, CD44+/CD24- was related to lymphovascular invasion, lymph node, and distant metastasis
Giatromanolaki et al. [31]	2010	139 cases of breast carcinomas (IDC) were investigated in paraffin sections using cell-like markers: (CD44, CD24), the ‘‘triple-state’’ (ER, PR, c-erb-B2), and angiogenesis (CD31)	Cases with CD44+/CD24- profile had a lower median age at onset of BC and showed a triple-negative state. They had a poor prognosis